School of Medicine
Showing 1-10 of 60 Results
Professor of Pathology
Current Research and Scholarly InterestsDr. Allisons clinical expertise is in breast pathology. Her research interests include how standards should be applied to breast cancer diagnostics (such as ER and HER2 testing), the utility of molecular panel-based testing in breast cancer, digital pathology applications and identifying the most appropriate management of specific pathologic diagnoses.
Associate Professor of Cardiothoracic Surgery (Thoracic Surgery)
BioLeah Backhus trained in general surgery at the University of Southern California and cardiothoracic surgery at the University of California Los Angeles. She practices at Stanford Hospital and is Chief of Thoracic Surgery at the VA Palo Alto. Her surgical practice consists of general thoracic surgery with special emphasis on thoracic oncology and minimally invasive surgical techniques. She is also Co-Director of the Thoracic Surgery Clinical Research Program, and has grant funding through the Veterans Affairs Administration and NIH. Her current research interests are in imaging surveillance following treatment for lung cancer and cancer survivorship. She is a member of the National Lung Cancer Roundtable of the American Cancer Society serving as Chair of the Task Group on Lung Cancer in Women. She also serves on the Board of Directors of the Society of Thoracic Surgeons. As an educator, Dr. Backhus is the Associate Program Director for the Thoracic Track Residency and is the Chair of the ACGME Residency Review Committee for Thoracic Surgery which is the accrediting body for all cardiothoracic surgery training programs in the US.
Associate Professor of Genetics
Current Research and Scholarly InterestsWe are an interdisciplinary lab focused on two major areas:(1) we seek to understand mechanisms of cancer growth and drug resistance in order to find new therapeutic targets(2) we study mechanisms by which macrophages and other cells take up diverse materials by endocytosis and phagocytosis; these substrates range from bacteria, viruses, and cancer cells to drugs and protein toxins. To accomplish these goals, we develop and use new technologies for high-throughput functional genomics.
Baker Family Director of Stanford ChEM-H, Anne T. and Robert M. Bass Professor in the School of Humanities and Sciences and Professor, by courtesy, of Chemical and Systems Biology and of Radiology
BioProfessor Carolyn Bertozzi's research interests span the disciplines of chemistry and biology with an emphasis on studies of cell surface sugars important to human health and disease. Her research group profiles changes in cell surface glycosylation associated with cancer, inflammation and bacterial infection, and uses this information to develop new diagnostic and therapeutic approaches, most recently in the area of immuno-oncology.
Dr. Bertozzi completed her undergraduate degree in Chemistry at Harvard University and her Ph.D. at UC Berkeley, focusing on the chemical synthesis of oligosaccharide analogs. During postdoctoral work at UC San Francisco, she studied the activity of endothelial oligosaccharides in promoting cell adhesion at sites of inflammation. She joined the UC Berkeley faculty in 1996. A Howard Hughes Medical Institute Investigator since 2000, she came to Stanford University in June 2015, among the first faculty to join the interdisciplinary institute ChEM-H (Chemistry, Engineering & Medicine for Human Health). She is now the Baker Family Director of Stanford ChEM-H.
Named a MacArthur Fellow in 1999, Dr. Bertozzi has received many awards for her dedication to chemistry, and to training a new generation of scientists fluent in both chemistry and biology. She has been elected to the Institute of Medicine, National Academy of Sciences, and American Academy of Arts and Sciences; and received the Lemelson-MIT Prize, the Heinrich Wieland Prize, the ACS Award in Pure Chemistry, and the Chemistry of the Future Solvay Prize, among others.
The Bertozzi Group develops chemical tools to study the glycobiology underlying diseases such as cancer, inflammation, tuberculosis and most recently COVID-19. She is the inventor of "bioorthogonal chemistry", a class of chemical reactions compatible with living systems that enable molecular imaging and drug targeting. Her group also developed new therapeutic modalities for targeted degradation of extracellular biomolecules, such as antibody-enzyme conjugates and Lysosome Targeting Chimeras (LYTACs). As well, her group studies NGly1 deficiency, a rare genetic disease characterized by loss of the human N-glycanase.
Several of the technologies developed in the Bertozzi lab have been adapted for commercial use. Actively engaged with several biotechnology start-ups, Dr. Bertozzi cofounded Redwood Bioscience, Enable Biosciences, Palleon Pharmaceuticals, InterVenn Bio, OliLux Bio, Grace Science LLC and Lycia Therapeutics. She is also a member of the Board of Directors of Lilly.
Professor of Pathology and of Microbiology and Immunology and, by courtesy, of Chemical and Systems BiologyOn Leave from 03/01/2023 To 12/31/2023
Current Research and Scholarly InterestsOur lab uses chemical, biochemical, and cell biological methods to study protease function in human disease. Projects include:
1) Design and synthesis of novel chemical probes for serine and cysteine hydrolases.
2) Understanding the role of hydrolases in bacterial pathogenesis and the human parasites, Plasmodium falciparum and Toxoplasma gondii.
3) Defining the specific functional roles of proteases during the process of tumorogenesis.
4) In vivo imaging of protease activity
Assistant Professor of Medicine (Oncology)
Current Research and Scholarly InterestsMy research is on the translational application of next-generation sequencing technologies to breast cancer care: (1) the value of hereditary cancer genetic panel testing in clinical practice, (2) the mechanisms by which inherited genetic variants lead to breast cancer development, and (3) the analysis of somatic tumor sequencing data to inform understanding of breast tumorigenesis, metastasis, and development of resistance in response to therapeutics.
James K. Chen
Jauch Professor and Professor of Chemical and Systems Biology, of Developmental Biology and of Chemistry
Current Research and Scholarly InterestsOur laboratory combines chemistry and developmental biology to investigate the molecular events that regulate embryonic patterning, tissue regeneration, and tumorigenesis. We are currently using genetic and small-molecule approaches to study the molecular mechanisms of Hedgehog signaling, and we are developing chemical technologies to perturb and observe the genetic programs that underlie vertebrate development.
Jennifer R. Cochran
Senior Associate Vice Provost for Research, Addie and Al Macovski Professor, Professor of Bioengineering and, by courtesy, of Chemical Engineering
Current Research and Scholarly InterestsMolecular Engineering, Protein Biochemistry, Biotechnology, Cell and Tissue Engineering, Molecular Imaging, Chemical Biology
A. Dimitrios Colevas, MD
Professor of Medicine (Oncology) and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) and of Radiation Oncology (Radiation Therapy)On Partial Leave from 01/02/2023 To 03/31/2023
Current Research and Scholarly InterestsMulti- modality treatment of Head and Neck Cancer
Phase 1 clinical trials
Steven M. Corsello
Assistant Professor of Medicine (Oncology) and, by courtesy, of Chemical and Systems Biology
Current Research and Scholarly InterestsOur laboratory operates at the intersection of functional genomics and chemical biology, with the goal of advancing novel molecular mechanisms of cancer inhibition to clinical use. We aim to 1) leverage phenotypic screening and functional genomics to determine novel anti-cancer mechanisms of small molecules, 2) develop new targeted therapy approaches against solid tumors, and 3) build a comprehensive community resource for drug repurposing discovery.